In a landmark decision, the Pretoria High Court has given the South African Pharmacy Council (SAPC) the judicial green light to implement its Pharmacy-Initiated Management of Antiretroviral Treatment (PIMART) initiative. This allows specially trained pharmacists to manage and prescribe medicine to patients with HIV and tuberculosis.
Judge Elmarie van der Schyff dismissed an application by a doctors’ organisation, the IPA Foundation, to set aside the programme, stating the need for wider access to first-line ART and TPT therapy on a community level is a “dire need”.
The PIMART training course was created to qualify pharmacists in safely and effectively assisting in providing ART, upon successful completion.
This ruling is in line with the World Health Organization’s vision to promote widely accessible primary health care and recognizes the critical role pharmacies play in meeting healthcare needs, especially during pandemics like COVID-19.
Professor Francois Venter, former President of the Southern African HIV Clinicians Society and current Director of Ezintsha, an HIV research organisation, has emphasized the crucial role of pharmacies and pharmacists in expanding HIV services worldwide.
Let’s celebrate this win.
🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.
A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.
#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1
💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?
A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.
Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.
#SyenzaNews #HealthEconomics #MarketAccess
🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?
This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.
Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!
#SyenzaNews #HealthEconomics #Innovation #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
